EMAIL: SFeldman@olshanlaw.com

DIRECT DIAL: 212.451.2234

 

February 7, 2025

 

VIA EDGAR

 

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn.:  Tim Buchmiller
  Office of Life Sciences

 

Re:OS Therapies Incorporated
Registration Statement on Form S-1 (No. 333-284631)

 

Ladies and Gentlemen:

 

On behalf of OS Therapies Incorporated, a Delaware corporation (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:30 p.m., Eastern time, on Thursday, February 13, 2025, or as soon as practicable thereafter.

 

Please advise the undersigned of the effectiveness of the Registration Statement.

 

 

Very truly yours,
   
 

/s/ Spencer G. Feldman

  Spencer G. Feldman

 

cc:Paul A. Romness, MPH

 

 

 

 

 

 

 

February 7, 2025

 

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn.:  Tim Buchmiller
  Office of Life Sciences

 

Re:OS Therapies Incorporated
Registration Statement on Form S-1 (No. 333-284631)

 

Ladies and Gentlemen:

 

OS Therapies Incorporated hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:30 p.m., Eastern time, on Thursday, February 13, 2025, or as soon as practicable thereafter.

 

Very truly yours,
   
  OS Therapies Incorporated
   
  By:

/s/ Paul A. Romness

    Paul A. Romness
    President and Chief Executive Officer